美国生物技术公司Monte Rosa Therapeutics(GLUE.US)在周一盘中暴涨128.63%,报收7.98美元,引发投资者高度关注。此前,公司宣布与瑞士制药巨头诺华(NVS.US)签署一项独家许可协议,导致股价大涨。
根据协议的条款,诺华将支付Monte Rosa 1.5亿美元的预付款,以获得后者用于自身免疫性疾病治疗的VAV1导向分子胶降解剂MRT-6160的全球独家开发、生产和商业化权利。MRT-6160是一种正在研究的VAV1分子胶降解剂,在针对多种免疫介导疾病的临床前模型中显示出有前景的活性。Monte Rosa还将有资格获得未来高达21亿美元的开发、监管和销售里程碑付款,以及美国境外净销售额的分层版税。
此次与诺华达成的协议,有望加快Monte Rosa 推进分子胶降解剂产品线的进度,并为公司带来长期收益。分子胶降解剂是一类利用人体蛋白质破坏机制选择性降解与某些疾病相关的异常蛋白质的新型小分子药物,被视为解决具有挑战性生物靶标的潜在手段。诺华生物医学研究总裁菲奥娜-马歇尔就表示:"诺华公司长期以来对分子胶降解剂一直很感兴趣,因为这种疗法有可能破解难以攻克的生物靶标。"
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.